# ENDRA Life Sciences Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ENDRA Life Sciences Inc.). ## Overview ENDRA Life Sciences Inc. is a U.S.-based medical technology company developing TAEUS, a thermo-acoustic enhanced ultrasound platform designed to measure liver fat at the point of care. The company’s first application targets metabolic disease detection and management, including support for GLP-1 therapy eligibility and monitoring, but it has not yet commercialized the technology or generated revenue. ## Products & services • TAEUS thermo-acoustic enhanced ultrasound platform • Liver fat measurement for metabolic disease assessment • GLP-1 therapy eligibility and monitoring tools • Subscription-based device access with monthly recurring revenue • Traditional device sales with annual upgrades and maintenance - **TAEUS diagnostic platform** (0%) — Thermo-acoustic enhanced ultrasound systems and related software for liver fat measurement. - **Metabolic disease assessment applications** (0%) — Clinical applications aimed at detecting and managing metabolic disease biomarkers. - **GLP-1 management applications** (0%) — Tools intended to support patient selection and monitoring for GLP-1 therapies. - **Subscription and service model** (0%) — Planned recurring-access model with monthly fees, upgrades, and maintenance. - **Direct product sales** (0%) — Traditional sale of the device to customers that prefer an upfront purchase model. - TAEUS thermo-acoustic enhanced ultrasound platform - Liver fat measurement for metabolic disease assessment - GLP-1 therapy eligibility and monitoring tools - Subscription-based device access with monthly recurring revenue - Traditional device sales with annual upgrades and maintenance ## Customers ENDRA is targeting clinical buyers that need a simple, point-of-care way to assess liver fat and related metabolic disease risk. Its stated go-to-market approach is a direct sales force selling into four markets, with the product positioned for clinicians and healthcare organizations that want biomarker-based decision support for metabolic disease and GLP-1 management. - **Point-of-care clinicians** (primary) — Buy TAEUS to measure liver fat quickly in office or clinic settings and support diagnosis. - **Metabolic disease management programs** (primary) — Use the platform to identify and track biomarkers tied to obesity, NAFLD, and related conditions. - **GLP-1 therapy providers** (secondary) — Use the device to help determine eligibility and monitor patients receiving GLP-1 treatments. - **Hospitals and imaging centers** (secondary) — May adopt the system for broader ultrasound-based assessment workflows and procedural use cases. - Clinics and providers assessing liver fat at point of care - Metabolic disease programs needing biomarker-based screening - GLP-1 prescribers managing therapy eligibility and follow-up - Healthcare organizations seeking lower-cost ultrasound workflows - Customers preferring subscription access over upfront purchase ## Geography ENDRA is headquartered in the United States and appears to conduct most of its development, financing, and commercialization planning from there. The company has not disclosed meaningful country revenue because it has not yet commercialized TAEUS, so geographic exposure is currently driven more by U.S. capital markets, regulatory approval, and clinical adoption than by sales mix. - Headquartered in the United States - Commercialization and regulatory work are centered on U.S. markets - No disclosed country revenue because the product is not yet sold - Exposure is tied to U.S. FDA approval and domestic capital access - Future sales could expand internationally after initial U.S. launch ## Strategy ENDRA’s strategy is to complete clinical development and obtain FDA approval for its NAFLD/liver-fat TAEUS system, then commercialize it through a low-barrier subscription model. Management is also emphasizing AI/ML enhancement, smaller form factor, and lower procedure time to improve usability and support adoption, while preserving a traditional sale option for some customers. - **FDA approval and clinical validation** (short-term) — Commercial launch depends on proving safety, accuracy, and clinical utility. - **Subscription-based commercialization** (medium-term) — Recurring revenue could lower customer adoption barriers and improve visibility. - **Product simplification and AI enhancement** (medium-term) — Better usability and accuracy are needed to compete in point-of-care imaging. - Advance TAEUS toward FDA approval for liver-fat assessment - Build a subscription model to create recurring revenue - Use direct sales supported by clinical data and reference sites - Apply AI and machine learning to improve measurement accuracy - Reduce device size, cost, and procedure time to aid adoption ## Risks ENDRA remains pre-revenue and depends on external financing to fund development, so liquidity risk is the dominant business issue. The company also faces regulatory, clinical, and commercialization risk because TAEUS still needs validation and FDA approval, while its new cryptocurrency treasury strategy adds volatility and regulatory uncertainty that is unrelated to the core medical device business. - **Liquidity and going-concern risk** [critical] — The company has limited cash and needs additional capital to continue operations and commercialization. - **Regulatory approval risk** [high] — TAEUS must obtain FDA approval before broad commercialization of the NAFLD system. - **Clinical validation and adoption risk** [high] — The platform must prove accuracy, utility, and ease of use versus existing imaging alternatives. - **Cryptocurrency price and regulatory risk** [high] — The company intends to hold digital assets, which can be highly volatile and may face securities-law scrutiny. - No commercial revenue yet, so the business depends on financing - FDA approval and clinical validation remain uncertain - Commercial adoption may be slow if workflow or value is unclear - Going-concern risk if capital is not raised on time - Crypto treasury exposure adds volatility and regulatory risk ## Accounting Because ENDRA is pre-revenue, reported results are driven mainly by R&D, G&A, stock compensation, and financing-related fair value changes rather than product sales. Investors should watch warrant liability remeasurement, share-based compensation, and estimates tied to going-concern assumptions, because these items can materially move reported earnings without reflecting operating progress. - **Warrant liability fair value** — Can materially distort net loss from quarter to quarter - **Share-based compensation** — Raises operating expenses without affecting cash immediately - **Going-concern assessment** — Affects investor assessment of solvency and dilution risk - **Fair value estimates and contingencies** — Can change reported liabilities and expenses materially - No revenue yet, so operating losses are driven by development spending - Warrant liability is remeasured at fair value each period - Share-based compensation affects reported operating expense - Going-concern disclosures reflect dependence on future financing - Estimates for contingencies and fair values can swing results --- *Last updated: 2026-04-28T20:03:07.525066+00:00*